

Shenda Orrego Molina

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8550688/shenda-orrego-molina-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

31
citations

3
h-index

5
g-index

13
ext. papers

39
ext. citations

1.9
avg, IF

1.63
L-index

| # | Paper | IF | Citations |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 13 | Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3385-3389 | 1.7 | 7 |
| 12 | Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse. <i>Ecancermedicalscience</i> , 2019, 13, 935 | 2.7 | 7 |
| 11 | Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. <i>Ecancermedicalscience</i> , 2019, 13, 934 | 2.7 | 5 |
| 10 | The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone. <i>Colorectal Disease</i> , 2021, 23, 805-813 | 2.1 | 3 |
| 9 | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecancermedicalscience</i> , 2020, 14, 1119 | 2.7 | 2 |
| 8 | Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. <i>Ecancermedicalscience</i> , 2020, 14, 1119 | 2.7 | 2 |
| 7 | Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study. <i>Urology Journal</i> , 2020, 17, 262-270 | 0.9 | 2 |
| 6 | Pregnancy in a 31-year-old woman with chronic lymphocytic leukemia: a case report and review of the literature. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 368-370 | 1.6 | 1 |
| 5 | The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. <i>Turkish Journal of Urology</i> , 2020, 46, 360-366 | 1.3 | 1 |
| 4 | Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2391-2397 | 1.7 | 1 |
| 3 | The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. <i>Turkish Journal of Urology</i> , 2020, 46, 360-366 | 1.3 | |
| 2 | The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer. <i>Turkish Journal of Urology</i> , 2020, 46, 186-195 | 1.3 | |
| 1 | The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy. <i>Ecancermedicalscience</i> , 2020, 14, 1063 | 2.7 | |